EPS: As of FY2025 Q3, the actual value is USD -2.57.

EBIT: As of FY2025 Q3, the actual value is USD -2.371 M.

Segment Revenue

• Revenue: The company reported no revenue for the three and nine months ended January 31, 2025, compared to $15,000 and $19,000 for the same periods in 2024, respectively.

Operational Metrics

• Net Loss: The net loss for the three months ended January 31, 2025 was $2.5 million, an increase from $1.6 million in the same period in 2024. For the nine months ended January 31, 2025, the net loss was $6.7 million, compared to $4.8 million in 2024.
• Research and Development Expenses: R&D expenses were $1.0 million for the three months ended January 31, 2025, up from $510,000 in 2024. For the nine months ended January 31, 2025, R&D expenses were $3.5 million, compared to $1.8 million in 2024.
• Selling, General and Administrative Expenses: These expenses were $1.3 million for the three months ended January 31, 2025, up from $1.0 million in 2024. For the nine months ended January 31, 2025, these expenses were $3.0 million, compared to $2.6 million in 2024.

Cash Flow

• Net Cash Used in Operating Activities: The company used $5.8 million in operating activities during the nine months ended January 31, 2025, compared to $4.5 million in 2024.
• Net Cash Used in Investing Activities: Cash used in investing activities was $22,000 for the nine months ended January 31, 2025, compared to $56,000 in 2024.
• Net Cash Provided by Financing Activities: Financing activities provided $2.6 million during the nine months ended January 31, 2025, compared to $10.0 million in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to seek FDA submission for the MyoVista wavECG in the first half of 2025 and aims for a submission of the MyoVista Insights Cloud Platform and low ejection fraction algorithm in the second half of 2025.
• Non-Core Business: The company is developing a cloud-based platform to host AI-ECG algorithms and has entered into multiple license agreements with Mount Sinai to commercialize AI cardiovascular algorithms.